The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor …
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor …
The Trump administration’s pick for Assistant Secretary for Preparedness and Response has a history of linking hepatitis B …
The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Clinical trial results underscore safety and diagnostic accuracy for radiopharmaceutical imaging; Clarity pursues regulatory filings and wider manufacturing …
June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
New data from India suggest that Hillchol, an oral cholera vaccine by Bharat Biotech, is safe, effective and …
Phase III ASCENT-04/KEYNOTE-D19 trial reveals meaningful PFS improvement with a novel antibody-drug conjugate/immunotherapy combo
Megafunding rounds and regulatory momentum reshaped the biotech investment landscape, signaling growing confidence in transformative clinical innovation.
Already a subscriber? Log in